Fig. 1: Physostigmine effects in Bipolar Disorder and Healthy Controls during the recognition of negative emotions. | Neuropsychopharmacology

Fig. 1: Physostigmine effects in Bipolar Disorder and Healthy Controls during the recognition of negative emotions.

From: Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex

Fig. 1

Panel shows the effects of physostigmine on functional activation and behavioural performance during the recognition of negative emotions. A increased activation in the right superior frontal gyrus (BA46, T = 4.11 p = 0.006) in BD receiving physostigmine relative to placebo; B decreased activation of the left anterior cingulate cortex (BA32, T = 4.03 p = 0.003) in controls receiving physostigmine relative to placebo. C increased activation within the bilateral dorsal cingulate cortices in BD receiving physostigmine relative to controls (BA31, T = 4.11, p < 0.001). Behavioural performance (accuracy and reaction times) remained unchanged (A–C). BD Bipolar Disorder; HC Healthy Controls. Phys Physostigmine; *pFWE-corr < 0.05; 10 voxel-cluster.

Back to article page